|
[PMID]: | 28253393 |
[Au] Autor: | Mustian KM; Alfano CM; Heckler C; Kleckner AS; Kleckner IR; Leach CR; Mohr D; Palesh OG; Peppone LJ; Piper BF; Scarpato J; Smith T; Sprod LK; Miller SM |
[Ad] Endereço: | Department of Surgery, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. |
[Ti] Título: | Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. |
[So] Source: | JAMA Oncol;3(7):961-968, 2017 Jul 01. | [Is] ISSN: | 2374-2445 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | Importance: Cancer-related fatigue (CRF) remains one of the most prevalent and troublesome adverse events experienced by patients with cancer during and after therapy. Objective: To perform a meta-analysis to establish and compare the mean weighted effect sizes (WESs) of the 4 most commonly recommended treatments for CRF-exercise, psychological, combined exercise and psychological, and pharmaceutical-and to identify independent variables associated with treatment effectiveness. Data Sources: PubMed, PsycINFO, CINAHL, EMBASE, and the Cochrane Library were searched from the inception of each database to May 31, 2016. Study Selection: Randomized clinical trials in adults with cancer were selected. Inclusion criteria consisted of CRF severity as an outcome and testing of exercise, psychological, exercise plus psychological, or pharmaceutical interventions. Data Extraction and Synthesis: Studies were independently reviewed by 12 raters in 3 groups using a systematic and blinded process for reconciling disagreement. Effect sizes (Cohen d) were calculated and inversely weighted by SE. Main Outcomes and Measures: Severity of CRF was the primary outcome. Study quality was assessed using a modified 12-item version of the Physiotherapy Evidence-Based Database scale (range, 0-12, with 12 indicating best quality). Results: From 17 033 references, 113 unique studies articles (11 525 unique participants; 78% female; mean age, 54 [range, 35-72] years) published from January 1, 1999, through May 31, 2016, had sufficient data. Studies were of good quality (mean Physiotherapy Evidence-Based Database scale score, 8.2; range, 5-12) with no evidence of publication bias. Exercise (WES, 0.30; 95% CI, 0.25-0.36; P < .001), psychological (WES, 0.27; 95% CI, 0.21-0.33; P < .001), and exercise plus psychological interventions (WES, 0.26; 95% CI, 0.13-0.38; P < .001) improved CRF during and after primary treatment, whereas pharmaceutical interventions did not (WES, 0.09; 95% CI, 0.00-0.19; P = .05). Results also suggest that CRF treatment effectiveness was associated with cancer stage, baseline treatment status, experimental treatment format, experimental treatment delivery mode, psychological mode, type of control condition, use of intention-to-treat analysis, and fatigue measures (WES range, -0.91 to 0.99). Results suggest that the effectiveness of behavioral interventions, specifically exercise and psychological interventions, is not attributable to time, attention, and education, and specific intervention modes may be more effective for treating CRF at different points in the cancer treatment trajectory (WES range, 0.09-0.22). Conclusions and Relevance: Exercise and psychological interventions are effective for reducing CRF during and after cancer treatment, and they are significantly better than the available pharmaceutical options. Clinicians should prescribe exercise or psychological interventions as first-line treatments for CRF. |
[Mh] Termos MeSH primário: |
Estimulantes do Sistema Nervoso Central/uso terapêutico Terapia Cognitiva Terapia por Exercício Fadiga/terapia Glucocorticoides/uso terapêutico Neoplasias/complicações Inibidores da Captação de Serotonina/uso terapêutico Promotores da Vigília/uso terapêutico
|
[Mh] Termos MeSH secundário: |
Compostos Benzidrílicos/uso terapêutico Cloridrato de Dexmetilfenidato/uso terapêutico Dextroanfetamina/uso terapêutico Fadiga/etiologia Seres Humanos Metilfenidato/uso terapêutico Metilprednisolona/uso terapêutico Paroxetina/uso terapêutico Psicoterapia
|
[Pt] Tipo de publicação: | COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW |
[Nm] Nome de substância:
| 0 (Benzhydryl Compounds); 0 (Central Nervous System Stimulants); 0 (Glucocorticoids); 0 (Serotonin Uptake Inhibitors); 0 (Wakefulness-Promoting Agents); 1678OK0E08 (Dexmethylphenidate Hydrochloride); 207ZZ9QZ49 (Methylphenidate); 41VRH5220H (Paroxetine); R3UK8X3U3D (modafinil); TZ47U051FI (Dextroamphetamine); V63XWA605I (armodafinil); X4W7ZR7023 (Methylprednisolone) |
[Em] Mês de entrada: | 1708 |
[Cu] Atualização por classe: | 170828 |
[Lr] Data última revisão:
| 170828 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170303 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1001/jamaoncol.2016.6914 |
|
|
|